An acetylation‐mimetic METTL3 variant disrupts this process, leading to diminished metastatic capacity, suggesting that METTL3's acetylation state is pivotal in modulating its oncogenic potential in breast cancer. The gene discussed is METTL3; the disease is breast cancer.